Fidaxomicin for the Treatment of <i>Clostridioides difficile</i> Infection in Adult Patients: An Update on Results from Randomized Controlled Trials

In recently updated international guidelines, fidaxomicin is preferentially recommended as first-line treatment over vancomycin both for the first episode of CDI and for rCDI, based on the results of different randomized controlled trials (RCTs). Although noninferiority was the rule in phase-3 RCTs...

Full description

Bibliographic Details
Published in:	Antibiotics
Main Authors:	Daniele Roberto Giacobbe, Antonio Vena, Marco Falcone, Francesco Menichetti, Matteo Bassetti
Format:	Article
Language:	English
Published:	MDPI AG 2022-10-01
Subjects:	fidaxomicin CDI rCDI <i>Clostridioides difficile</i> randomized clinical trials RCT
Online Access:	https://www.mdpi.com/2079-6382/11/10/1365

Similar Items

The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
by: Ronald G. Hall, et al.
Published: (2022-02-01)

Alternative treatment of recurrent Clostridioides difficile infection in adults by fecal transplantation: an overview of phase I–IV studies from Clinicaltrials.gov
by: Najla A. Obaid
Published: (2024-05-01)

Does Fidaxomicin reduce Cure and Recurrence rates compared to Vancomycin in Clostridium Difficile Infection patients?: A Systematic Review and Meta-analysis
by: Hiral N Golakiya, et al.
Published: (2022-06-01)

Bezlotoxumab in Patients with a Primary <i>Clostridioides difficile</i> Infection: A Literature Review
by: Guido Granata, et al.
Published: (2022-10-01)

Editorial: Clostridioides difficile infection
by: Guido Granata, et al.
Published: (2024-02-01)

Against <i>Clostridioides difficile</i> Infection: An Update on Vaccine Development
by: Jingyao Wang, et al.
Published: (2025-05-01)

Can Gut Microbiota Analysis Reveal <i>Clostridioides difficile</i> Infection? Evidence from an Italian Cohort at Disease Onset
by: Roberto Rosato, et al.
Published: (2024-12-01)

Trends in and Risk Factors for Recurrent Clostridioides difficile Infection, New Haven County, Connecticut, USA, 2015–2020
by: Chinenye M. Okafor, et al.
Published: (2023-05-01)

The Role of Bezlotoxumab for the Prevention of Recurrent <i>Clostridioides difficile</i> Infections: A Review of the Current Literature and Paradigm Shift after 2021
by: Melanie L. Hyte, et al.
Published: (2022-09-01)

<i>Clostridioides difficile</i> in Peripartum Women: Review of Outcomes and Treatment
by: Ravina Kullar, et al.
Published: (2025-08-01)

Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study
by: Marcos Hernando-Gozalo, et al.
Published: (2024-05-01)

Recognition, Diagnosis, and Treatment of <i>Clostridioides difficile</i> Enterocolitis Presenting Without Diarrhea: A Literature Review
by: Ezgi Yılmaz, et al.
Published: (2025-02-01)

National Surveillance for Clostridioides difficile Infection, Sweden, 2009–2016
by: Kristina Rizzardi, et al.
Published: (2018-09-01)

Increase of Clostridioides difficile PCR ribotype 002 infection with decreased disease severity in hospitalized patients in the Netherlands
by: A. Baktash, et al.
Published: (2025-10-01)

Potential for Misinterpretation in the Laboratory Diagnosis of <i>Clostridioides difficile</i> Infections
by: Alexandra Kalacheva, et al.
Published: (2025-05-01)

Assessing the Feasibility of Employing a Combination of a Bacteriophage-Derived Endolysin and Spore Germinants to Treat Relapsing <i>Clostridioides difficile</i> Infection
by: Khalid Alyahya, et al.
Published: (2023-06-01)

Systematic review of guidelines for the diagnosis and treatment of Clostridioides difficile infection
by: Ting Gu, et al.
Published: (2022-08-01)

<i>Clostridioides difficile</i> and Gut Microbiota: From Colonization to Infection and Treatment
by: Patrizia Spigaglia
Published: (2024-07-01)

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent <i>Clostridioides difficile</i> Infection (rCDI)
by: Sahil Khanna, et al.
Published: (2022-09-01)

Cell Wall Protein 2 as a Vaccine Candidate Protects Mice Against <i>Clostridioides difficile</i> Infection
by: Shaohui Wang, et al.
Published: (2024-12-01)

Influence of Probiotics on the Development of <i>Clostridioides difficile</i> Infection in Patients Receiving Fluoroquinolones
by: Mary E. Sheffield, et al.
Published: (2021-08-01)

<i>Clostridioides difficile</i> in Pigs and Dairy Cattle in Northern Italy: Prevalence, Characterization and Comparison between Animal and Human Strains
by: Patrizia Spigaglia, et al.
Published: (2023-07-01)

Environmental and Nutritional Parameters Modulating Genetic Expression for Virulence Factors of <i>Clostridioides difficile</i>
by: Zoe Masset, et al.
Published: (2024-04-01)

Molecular epidemiology and clinical risk factors for rifaximin-non-susceptible Clostridioides difficile infection in South Korea: a prospective, multicentre, observational study
by: Dokyun Kim, et al.
Published: (2021-12-01)

Risks and Preventive Strategies for Clostridioides difficile Transmission to Household or Community Contacts during Transition in Healthcare Settings
by: Ramin Asgary, et al.
Published: (2021-07-01)

Clostridioides difficile infection and recurrence in cancer patients (CIRCA): A multicentre, international study
by: Pedro Puerta-Alcalde, et al.
Published: (2025-04-01)

Comparative Efficacy of Fecal Microbiota Transplantation in Treating Refractory or Recurrent <i>Clostridioides difficile</i> Infection among Patients with and without Inflammatory Bowel Disease: A Retrospective Cohort Study
by: Jing-Han Chen, et al.
Published: (2024-06-01)

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of <i>Clostridioides difficile</i> Infection
by: Laura Whitney, et al.
Published: (2023-01-01)

Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating <i>Clostridioides difficile</i> Infection and the Associated Recurrence Rate: A Retrospective Cohort Study
by: Nobuaki Mori, et al.
Published: (2023-08-01)

Updated Management Guidelines for <i>Clostridioides difficile</i> in Paediatrics
by: Margherita Gnocchi, et al.
Published: (2020-04-01)

Clostridioides difficile infection study models and prospectives for probing the microbe-host interface
by: Tatiana Zvonareva, et al.
Published: (2025-03-01)

ESTRATÉGIAS PARA REDUÇÃO DOS CASOS DE CLOSTRIDIOIDES DIFFICILE NA UNIDADE DE TERAPIA INTENSIVA: ABORDAGEM MULTIFATORIAL
by: Luciana Rodrigues da Silva, et al.
Published: (2023-10-01)

A Real-World Study on the Clinical Characteristics, Outcomes, and Relationship between Antibiotic Exposure and <i>Clostridioides difficile</i> Infection
by: Bogdan Ioan Vintila, et al.
Published: (2024-02-01)

Dietary iron attenuates Clostridioides difficile infection via modulation of intestinal immune response and gut microbiota
by: Xiao Li, et al.
Published: (2025-12-01)

Characterization of Adult and Pediatric Healthcare-Associated and Community-Associated Clostridioides difficile Infections, Canada, 2015–2022
by: Tim Du, et al.
Published: (2025-06-01)

Clinical significance of toxin EIA positivity in patients with suspected Clostridioides difficile infection: systematic review and meta-analysis
by: Giannoula S. Tansarli, et al.
Published: (2025-01-01)

<i>Clostridioides difficile</i> infection in hospital and community settings: summary document of a multidisciplinary group
by: Anna Danise, et al.
Published: (2024-02-01)

Clostridioides difficile infection in infants: a case report and literature review
by: Zhirong Li, et al.
Published: (2023-06-01)

Characterization of the gut microbiome of patients with Clostridioides difficile infection, patients with non–C. difficile diarrhea, and C. difficile–colonized patients
by: Silvia Vázquez-Cuesta, et al.
Published: (2023-04-01)

Clostridioides difficile Infection: Updates on Epidemiologic Patterns, Diagnostic Tools, and Treatment Modalities
by: Lamiaa Abd El-Fattah MADKOUR
Published: (2023-07-01)